Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.COVID-19 UPDATES
Novavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.Build your future with us
Join other passionately curious people who are bringing innovative vaccines to the world
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
The case for COVID-19 vaccines for children
For many of us, making decisions involves weighing up the benefits versus the risks. However, making decisions for someone else—particularly those more vulnerable—can be more complex. With the rapid rollout of COVID-19 vaccines and over 2 years of constant media coverage, misinformation and misunderstandings have flourished.
The benefits of vaccination for children
Although SARS-CoV-2 infection typically causes less severe illness and fewer deaths in children and adolescents than adults, there are still a number of benefits from vaccination1:
Direct benefits for children:
- Helping to protect them against severe COVID-19 and postinfectious conditions, such as "long COVID" (ongoing health problems) and multisystem inflammatory syndrome in children (MIS-C)1-4
- MIS-C is a rare inflammatory reaction in the body that occurs about 4 weeks after infection with SARS-CoV-2, usually in children aged 8 or 9 years. The inflammation can affect the heart, blood vessels, and other organs, which can be dangerous. Fortunately, if treated quickly, most children recover fully5
Indirect benefits of vaccination:
- Helping to protect the community by reducing transmission of SARS-CoV-21-4
- By reducing viral transmission, emergence of variants may be slowed down3,6
- Variants could be more contagious or resistant to currently effective vaccines and therapies3
- By helping to reduce the transmission of SARS-CoV-2 in schools, disruptions to children’s education and their participation in activities are minimized1
What is the clinical trial process like for children?
Normal practice for pediatric trials involves beginning them only when a vaccine has already been shown to be well tolerated and effective in adults,3 and are usually deferred until trials reach phase 3.7 Phase 3 trials compare the safety and efficacy of the new intervention against the current standard intervention or placebo.7 Pediatric trials can help researchers determine the most efficacious dose of vaccine with the least amount of side effects in children.
When planning a pediatric trial, there are a number of important considerations:
- Diversity: Like all clinical trials, it is imperative that they involve people from diverse backgrounds to ensure that trial results are as relevant as possible to all members of the population3
- Safety: As children’s immune systems have not yet been exposed to many pathogens, they tend to produce a strong immune response to vaccines.4 This means that children are more likely than adults to develop some side effects after vaccination, such as a fever.4 Therefore, a vaccine must have a good benefit-to-risk profile, triggering a strong immune response with minimal side effects4
- Informed consent: Parents play a key role in making decisions about the medical treatment of their children, and give informed consent prior to medical interventions.8 Information about the trial has to be given to children through an age-appropriate method to help them understand what is happening.7 The consent process should be culturally sensitive3
Before pediatric clinical trials can begin, they need to pass rigorous ethical evaluations and meet certain standards.7
Ongoing vaccination programs
The number of available and authorized COVID-19 vaccines for use in adults is growing, with programs slowly being extended to children.3
- World Health Organization. Interim statement on COVID-19 vaccination for children. Available at: https://www.who.int/news/item/11-08-2022-interim-statement-on-covid-19-vaccination-for-children [Accessed August 2022].
- Klass P, Ratner AJ. Vaccinating children against Covid-19—the lessons of measles. N Engl J Med. 2021 Feb 18;384(7):589–91.
- Atuire CA, Salas SP, Wright K, Ambe JR, de Vries J. COVID-19 vaccine trials with children: ethics pointers. BMJ Glob Health. 2022 Jan 1;7(1):e007466.
- Callaway E. COVID vaccines and kids: five questions as trials begin. Nature. 2021 Apr 21;592(7856):670-1.
- Johns Hopkins Medicine. MIS-C and COVID-19: uncommon but serious inflammatory syndrome in kids and teens. Available at: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/misc-and-covid19-rare-inflammatory-syndrome-in-kids-and-teens [Accessed August 2022].
- Van Egeren D, Novokhodko A, Stoddard M, et al. Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure. Sci Rep. 2021 Nov 19;11(1):22630.
- Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 2015 Mar;79(3):357-69.
- Wilkinson D, McBride AKS. Clinical ethics: consent for vaccination in children. Arch Dis Child. 2022 Jan;107(1):3-4.